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Abstract
Purpose To determine the eVect of body mass index (BMI)
on clinical and pathological characteristics at time of diagno-
sis and on risk of biochemical recurrence after radical prosta-
tectomy among Dutch men diagnosed with prostate cancer.
Methods In total, 1,116 prostate cancer patients with
known BMI, diagnosed between 2003 and 2006, were iden-
tiWed from the population-based cancer registry held by the
Comprehensive Cancer Centre East, The Netherlands. Of
these, 504 patients underwent a radical prostatectomy.
Patients were categorized as normal weight (BMI < 25 kg/m2),
overweight (BMI 25–30 kg/m2), or obese (BMI ¸
30 kg/m2). Multivariable proportional hazards regression
models, adjusted for age, prediagnostic PSA levels, and
pathological characteristics were used to evaluate BMI as a
prognostic factor for biochemical recurrence after radical
prostatectomy.
Results Overall, clinical and biopsy characteristics did not
signiWcantly diVer among BMI groups. Pathological charac-
teristics after radical prostatectomy did not signiWcantly
diVer among BMI groups, except for tumor stage, which
was highest in obese patients (P = 0.017). For patients
treated with radical prostatectomy, 5-year risk (95% ConW-
dence Intervals) of biochemical recurrence was 30% (23–
37%) for normal weight, 32% (25–39%) for overweight,
and 25% (9–41%) for obese patients (log rank P = 0.810).
BMI was not an independent prognostic factor for biochem-
ical recurrence in multivariable proportional hazards regres-
sion analyses (HR 0.99 per kg/m2, 95% CI: 0.93–1.06).
Conclusions Compared with non-obese men, pathological
tumor stage tended to be higher in obese men. Clinical rele-
vance of this Wnding is unclear, because BMI was not an
independent predictor of biochemical recurrence after radi-
cal prostatectomy.
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Introduction
It has been hypothesized that obesity is a risk factor for the
development and progression of prostate cancer (PC),
although results are inconsistent. Most studies focusing on
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World J Urolbody size and PC were conducted in the United States, where
a rapidly growing epidemic of obesity is reported with over
66% of adult Americans being overweight or obese [1]. In
Europe, incidence of overweight and obesity is also increas-
ing substantially [2]. Whether body size predisposes to
adverse PC characteristics or outcome in European men is a
matter of debate. Only few European studies examined
eVects of BMI on adverse pathological Wndings after biopsy
or radical prostatectomy (RP) [3–6]. Gallina and colleagues
suggested that high-grade PC at RP might be more prevalent
among obese men; however, adding BMI to the multivariable
model failed to increase predictive accuracy for high-grade
PC [6]. Other studies did not Wnd an association for BMI and
tumor grade or stage, extracapsular extension, seminal vesi-
cle invasion, lymph node involvement or positive surgical
margins either [3–5]. Results for PC outcome are inconclu-
sive as well. One study from Germany reported BMI as inde-
pendent predictor of biochemical recurrence (BCR) after RP,
although it did not improve predictive accuracy [7], while we
and others did not Wnd any eVect of BMI on BCR rates after
RP [5, 8] or brachytherapy [9].
Since results are conXicting and the epidemic of obesity
is growing, additional evidence on the eVects of body size
on PC risk and prognosis in Europe are needed. Aim of the
present study was to determine eVects of BMI on clinical
and pathological Wndings at time of diagnosis and on risk of
BCR after RP among Dutch men with PC.
Subjects and methods
Patients diagnosed with PC were identiWed from the popu-
lation-based cancer registry held by the Comprehensive
Cancer Centre East (CCCE), The Netherlands. From 2003
to 2006, 1,668 patients with PC were identiWed in this
region. Only patients with known BMI data were included
in our analyses (n = 1,116). For all patients, clinical data
were collected retrospectively by review of the clinical
charts. Part of the patients (n = 951), who were diagnosed
before the age of 76, participated in the POLYGENE pro-
ject [10] and Wlled out a postal questionnaires as part of it.
Self-reported weight and length were collected either from
the POLYGENE questionnaire (n = 943) or from the clini-
cal charts (n = 173) and were used to calculate BMI. For
278 patients, BMI was available from the questionnaire as
well as from the charts (Spearman r = 0.81, P < 0.001). For
these patients, BMI from the questionnaire was used in the
analyses. BMI categories were deWned according to the
WHO criteria: BMI < 25 kg/m2 (normal weight), BMI 25–
30 kg/m2 (overweight), and BMI ¸ 30 kg/m2 (obesity). The
institutional review board approved the study, and all par-
ticipants of the POLYGENE project provided written
informed consent.
Primary treatments were categorized as radical prosta-
tectomy (RP) with or without neoadjuvant androgen-depri-
vation therapy (ADT), radiotherapy (RT, including external
beam radiation and brachytherapy) with or without ADT,
active surveillance (AS), androgen-deprivation therapy
(ADT), and others (such as cryotherapy and chemother-
apy). In total, 517 patients who underwent RP as primary
therapy were identiWed. Patients treated with neoadjuvant
ADT (n = 13) were excluded, leaving 504 patients for anal-
ysis. BMI was evaluated as prognostic factor for BCR,
which is deWned as two consecutive PSA levels ¸0.2 ng/ml.
For these analyses, 11 patients were excluded, because data
on post-operative PSA levels or BCR status were missing.
After RP, patients were generally seen after 6 weeks, 3, 6,
9, and 12 months and then every 6 months, according to the
national guidelines for PC follow-up [11]. RP specimens
were processed according to protocols from the institutes
where patients were submitted to. Gleason grade was pre-
sented as the sum of two main Gleason scores. Clinical and
pathological stages were classiWed according to the 2002
TNM classiWcation based on the American Joint Committee
on Cancer guidelines (AJCC) [12].
We used Kruskal–Wallis tests to assess the association
between BMI categories and continuous clinical and patho-
logical variables, while Chi-square tests were applied to
categorical variables. Risk of BCR was calculated with the
Kaplan–Meier method, using the log-rank test to compare
BMI groups. Univariable and multivariable proportional
hazards regression analyses adjusted for age, prediagnostic
PSA levels, and pathological variables (Gleason score at
RP, pathological stage, surgical margin status, and lymph
node status) were performed to evaluate whether BMI is a
prognostic factor for BCR after RP. The signiWcance level
was set at P < 0.05, and all P values were two tailed.
Statistical Package of Social Sciences (SPSS, version 16.0,
Chicago, Illinois) was used for all analyses.
Results
Patient characteristics are shown in Table 1. Among all PC
patients included in the analyses (n = 1,116), median age at
diagnosis was 66.3 (inter-quartile range: 61.2–70.5) years.
Median BMI was 25.3 (IQR: 23.9–27.0) kg/m2, with 47%
of this population being overweight and 7% obese. Overall,
no statistically signiWcant diVerences for clinical or patho-
logical Wndings were observed among the BMI groups.
Although not statistically signiWcant, obese patients were
somewhat less likely to be referred for RP compared to nor-
mal weight and overweight patients (38% versus 46% and
48%, respectively).
Table 2 shows characteristics of patients with PC who
underwent RP. Median age and BMI of patients treated123
World J Urolwith RP were 63.3 (IQR: 58.8–67.1) years and 25.3 (IQR:
23.7–26.9) kg/m2. Pathological characteristics after RP did
not signiWcantly diVer between BMI groups, except for
tumor (pT) stage which was somewhat higher in obese
patients (P = 0.017). Furthermore, obese patients tended to
have higher prediagnostic PSA levels compared to over-
weight and normal weight patients (P = 0.004). BMI pre-
sented as a continuous variable, however, was only weakly
correlated with prediagnostic PSA levels (Spearman
r = 0.13, P = 0.004). Median follow-up of patients treated
with RP was 40.3 (IQR: 19.5–53.1) months. In total, 142
patients developed BCR after RP. The 5-year risk (95% CI)
of BCR was 30% (23–37%), 32% (25–39%), and 25%
(9–41%) for normal weight, overweight, and obese patients,
respectively (log rank P = 0.810) (Fig. 1).
As presented in Table 3, BMI was not a signiWcant prog-
nostic factor for BCR after RP in univariable (HR 1.02
per kg/m2, 95% CI: 0.97–1.07) or multivariable (HR 0.99
per kg/m2, 95% CI: 0.93–1.06) analyses after adjustment
for age, prediagnostic PSA, Gleason score at RP, positive
surgical margins, positive lymph nodes, and pathological
stage. Higher Gleason score, pathological stage, and positive
Table 1 Demographic, clinical, and pathological characteristics of Dutch patients diagnosed with prostate cancer according to BMI categories
Data presented as median (IQR) or number (%)
Percentages may not add up to 100% because of missing values
ADT androgen-deprivation therapy, AS active surveillance, BMI body mass index, cTNM clinical tumor-node-metastasis, PSA prostate speciWc
antigen, RP radical prostatectomy, RT radiotherapy
a Missing n = 243
b Missing n = 12
Total group BMI < 25 kg/m2 BMI 25–30 kg/m2 BMI ¸ 30 kg/m2 P value
Number of patients (%) 1,116 (100%) 510 (46%) 530 (47%) 76 (7%) –
Age at diagnosis (years) 66.3 (61.2–70.5) 66.1 (61.5–71.0) 66.2 (61.0–70.2) 65.1 (61.1–69.6) 0.753
BMI (kg/m2) 25.3 (23.9–27.0) 23.7 (22.9–24.4) 26.6 (25.8–27.8) 31.6 (30.7–33.6) –
BMI at age 18 (kg/m2)a 22.2 (21.0–23.7) 21.5 (20.2–22.6) 23.0 (21.8–24.2) 24.4 (23.1–28.1) –
Height (cm) 177 (172–182) 178 (173–183) 176 (172–180) 175 (172–179) –
Weight (kg) 80 (74–85) 75 (70–80) 83 (80–90) 100 (92–104) –
Smoking (%)
Never 170 (15%) 86 (17%) 74 (14%) 10 (13%) 0.035
Former 641 (57%) 285 (56%) 321 (61%) 35 (46%)
Current 136 (12%) 80 (16%) 50 (9%) 6 (8%)
Family history of prostate cancer (%)
Yes 228 (20%) 101 (20%) 117 (22%) 10 (13%) 0.285
No 736 (66%) 357 (70%) 336 (63%) 43 (57%)
Prediagnostic PSA level (ng/ml)b 10 (6–20) 9 (6–20) 10 (7–21) 10 (7–27) 0.187
Gleason score biopsy (%)
<7 689 (62%) 331 (65%) 316 (60%) 42 (55%) 0.128
7 226 (20%) 88 (17%) 120 (23%) 18 (24%)
>7 120 (11%) 49 (10%) 61 (12%) 10 (13%)
Clinical stage (cTNM) (%)
cT1 447 (40%) 200 (39%) 224 (42%) 23 (30%) 0.229
cT2 418 (38%) 196 (38%) 194 (37%) 28 (37%)
cT3 or cT4 233 (21%) 107 (21%) 104 (20%) 22 (29%)
Primary treatment (%)
Active surveillance (AS) 121 (11%) 58 (11%) 57 (11%) 6 (8%) 0.585
RP without ADT 504 (45%) 230 (45%) 245 (46%) 29 (38%)
RP with ADT 13 (1%) 4 (1%) 9 (2%) –
RT without ADT 115 (10%) 60 (12%) 46 (9%) 9 (12%)
RT with ADT 210 (19%) 94 (19%) 100 (18%) 16 (21%)
ADT 138 (12%) 58 (11%) 66 (12%) 14 (18%)
Others 10 (1%) 5 (1%) 4 (1%) 1 (1%)123
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Data presented as median (IQR) or numbers (%)
BMI body mass index, PSA prostate speciWc antigen, pTNM pathological tumor-node-metastasis, RP radical prostatectomy
a Missing n = 5
b Including 36 patients who did not reach post-operative PSA levels <0.2 ng/ml
Total group BMI < 25 kg/m2 BMI 25–30 kg/m2 BMI ¸ 30 kg/m2 P value
Number of patients (%) 504 (100%) 230 (46%) 245 (49%) 29 (6%) –
Age at RP (years) 63.3 (58.8–67.1) 63.4 (58.7–66.7) 63.2 (58.8–67.4) 63.0 (59.3–67.8) 0.961
BMI (kg/m2) 25.3 (23.7–26.9) 23.7 (22.9–24.4) 26.6 (25.8–27.7) 31.3 (30.5–34.3) –
Prediagnostic PSA (ng/ml)a 8 (6–12) 7 (5–10) 8 (6–13) 8 (5–12) 0.004
Follow-up (months) 40.3 (19.5–53.1) 40.9 (24.7–53.8) 39.4 (17.0–52.4) 40.6 (17.1–57.0) 0.502
Surgery (%)
Open 284 (56%) 123 (53%) 145 (59%) 16 (55%) 0.251
Laparoscopic 195 (39%) 99 (43%) 88 (36%) 8 (28%)
Missing 25 (5%) 8 (3%) 12 (5%) 5 (17%)
PSA nadir < 0.2 ng/ml (%)
Yes 461 (91%) 213 (93%) 221 (90%) 27 (93%) 0.853
No 36 (7%) 15 (7%) 19 (8%) 2 (7%)
Missing 7 (1%) 2 (1%) 5 (2%) 0
Biochemical recurrence (%)
Yesb 142 (28%) 65 (28%) 70 (29%) 7 (24%) 0.874
No 351 (70%) 163 (71%) 167 (68%) 21 (72%)
Missing 11 (2%) 2 (1%) 8 (3%) 1 (3%)
Gleason score RP (%)
<7 348 (69%) 165 (72%) 162 (66%) 21 (72%) 0.148
7 111 (22%) 44 (19%) 60 (24%) 7 (24%)
>7 30 (6%) 10 (4%) 20 (8%) 0
Missing 15 (3%) 11 (5%) 3 (1%) 1 (3%)
Pathological stage (pTNM) (%)
pT2 349 (69%) 170 (74%) 165 (67%) 14 (48%) 0.017
pT3 or pT4 143 (28%) 54 (23%) 76 (31%) 13 (45%)
Missing 12 (2%) 6 (3%) 4 (2%) 2 (7%)
Surgical margins (%)
Positive 211 (42%) 93 (40%) 102 (42%) 16 (55%) 0.341
Negative 270 (54%) 125 (54%) 133 (54%) 12 (41%)
Missing 23 (5%) 12 (5%) 10 (4%) 1 (3%)
Extracapsular extension (%)
Yes 175 (35%) 72 (31%) 89 (36%) 14 (48%) 0.204
No 221 (44%) 102 (44%) 110 (45%) 9 (31%)
Missing 108 (21%) 56 (24%) 46 (19%) 6 (21%)
Invasion seminal vesicles (%)
Yes 45 (9%) 15 (7%) 25 (10%) 5 (17%) 0.068
No 446 (88%) 211 (92%) 214 (87%) 21 (72%)
Missing 13 (3%) 4 (2%) 6 (2%) 3 (10%)
Lymph node dissection (%) 230 (46%) 83 (36%) 131 (53%) 16 (55%) 0.001
Positive lymph nodes (%) 17 (3%) 6 (3%) 9 (4%) 2 (7%) 0.726123
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of risk of BCR after RP.
Discussion and conclusion
In the present study among Dutch men diagnosed with PC,
BMI was weakly associated with higher pathological tumor
(pT) stage and higher prediagnostic PSA levels in patients
treated with RP. Gleason score, pathological stage, and pos-
itive surgical margins were independent predictors of BCR,
whereas BMI did not add any prognostic value in multivar-
iable proportional hazards regression analyses.
Our Wndings are consistent with other European studies
which did not Wnd a prognostic eVect of BMI in patients
treated with RP [5, 8]. Only one study reported a trend
toward statistical signiWcance for BMI as independent
prognostic factor for BCR [7]. Addition of BMI to a multi-
variable model, however, did not signiWcantly increase pre-
dictive accuracy [7]. Whereas most European studies so far
were not able to Wnd an association between BMI and any
clinical or pathological characteristics, several studies from
the United States did report BMI as predictor of BCR and
adverse pathological Wndings after RP [13–15]. These
inconsistent results might be explained by the lower rates of
obesity and severe obesity in Europe compared to the
United States [1, 2].
A remarkable observation in this study is the weak posi-
tive association between BMI and prediagnostic PSA levels
among RP patients, which was not observed in the overall
study population. Several studies observed an inverse asso-
ciation between BMI and prediagnostic PSA levels [16,
17]. Based on the theory of hemodilution, it has been
hypothesized that obese patients have larger plasma or
serum volumes, which may lead to lower PSA concentra-
tions [16]. It has also been suggested that lower PSA levels
in obese patients might result from decreased androgenic
activity [18]. Our results indicated a weak correlation
between BMI and PSA levels and were limited to a small
subpopulation of patients treated with RP; therefore, we
cannot rule out that our result was a chance Wnding.
Another Wnding of our study was the association
between BMI and pathological tumor (pT) stage among RP
patients, suggesting that advanced-staged tumors were
more common among obese patients. As reviewed by oth-
ers, obesity might indeed play a role in PC aggressiveness,
i.e. high stage, high grade, and increased risk of recurrence
or mortality [19]. It has been hypothesized that both non-
biological and biological mechanisms can be responsible
for the association between tumor aggressiveness and body
size. Firstly, it might be more diYcult to detect (early) PC
in obese men, due to lower PSA levels [16, 17] and diYcult
digital rectal examinations [19]. Secondly, diYculties
related to treatment might be responsible for an aggressive
type of PC in obese men. Pathological Wndings related to
technical aspects of surgery like positive surgical margins,
however, would be more likely to be aVected than tumor
grade or stage. Finally, alterations in levels of steroid hor-
mones, adipokines, and inXammatory mediators might also
drive PC toward a more aggressive form in obese men
[19, 20].
Evidence is growing that diVerentiation between total
adiposity and distribution of adipose tissue is relevant in the
studies related to obesity and PC. Recent studies suggested
that measures of body fat distribution might be better pre-
dictors of PC risk and prognosis when compared to BMI
[21, 22]. Fat distribution measurements usually distinct
subcutaneous fat from visceral fat depots or simply indicate
the location of adipose tissue. Skin fold measurements,
waist circumference, and waist-to-hip ratios are frequently
used estimates for the amount and location of adipose tis-
sue. Magnetic resonance imaging (MRI) and computed
tomography (CT) are considered more reliable methods for
assessing subcutaneous and visceral fat content [23]. Von
Hafe et al. [22] examined the relation between abdominal
visceral fat accumulation, as measured by CT, and PC inci-
dence within a case–control study. They found that visceral
fat area and visceral to subcutaneous fat ratio were strongly
associated with increased PC risk (crude OR 4.6, 95% CI:
2.6–8.2 and OR 6.0, 95% CI: 2.3–11.0, respectively).
Unfortunately, we did not have data on any measures of fat
distribution. Other potential limitations of our study might
Fig. 1 The 5-year risk of biochemical recurrence in normal weight,
overweight, and obese prostate cancer patients treated with radical pro-
statectomy (n = 493). Log rank P = 0.810)123
World J Urolbe its retrospective data collection, self-reported BMI, rela-
tively short follow-up (median 40.3 months), and small
number of patients, especially in the obese group. Results
therefore need to be interpreted with some caution. We can-
not exclude the possibility that the relatively large number
of missing values for BMI might have been a source of
selection bias, although the observation that patients with
missing BMI did not have more advanced tumor character-
istics compared to the patients with evaluable BMI in our
RP cohort (data not shown) argues against this. The
absence of an association between BMI and BCR might
also be explained by treatment-related selection. If obese
patients tend to have more advanced tumor characteristics
at diagnosis, and therefore have other types of treatment
(e.g. ADT), while mainly normal weight, low-risk patients
will have surgery, a possible association between BMI and
BCR could be missed. Our aim was, however, to study the
association between BMI and BCR in an average popula-
tion-based RP cohort. We conclude from our results that in
this cohort, BMI does not have any prognostic value for
risk of BCR. Whether BMI is associated with risk of recur-
rence in other treatment groups should be veriWed in the
future studies.
In summary, BMI did not aVect clinical or pathological
characteristics of PC patients at time of diagnosis. Com-
pared with non-obese men, pathological stage tended to be
higher in obese men treated with RP. Clinical relevance of
these Wndings with respect to risk of BCR, however, needs
Table 3 Univariable and multivariable proportional hazards regression models predicting biochemical recurrence after radical prostatectomy
(RP)
BMI body mass index, PSA prostate speciWc antigen, pTNM pathological tumor-node-metastasis, RP radical prostatectomy
a Variables in the multivariable model are adjusted for each other
b Replacing pathological stage by extracapsular extension and seminal vesicles invasion in the multivariable model resulted in adjusted hazards
ratios (95% CI) of 1.45 (0.92–2.28, P = 0.106) for extracapsular extension and 1.06 (0.59–1.91, P = 0.845) for seminal vesicles invasion, while
the adjusted hazards ratios for the remaining variables hardly changed
c The reference category is: no lymph node dissection performed or no positive lymph nodes
n Univariable Multivariable (n = 444)a,b
HR 95% CI P values Adjusted HR 95% CI P values
BMI (kg/m2) 493 1.02 0.97–1.07 0.525 0.99 0.93–1.06 0.732
BMI 493
<25 kg/m2 1.00 – –
25–30 kg/m2 1.08 0.77–1.51 0.658
¸30 kg/m2 0.90 0.41–1.96 0.789
Age at RP (years) 493 1.05 1.02–1.08 0.003 1.02 0.98–1.05 0.396
Surgery 472
Open 1.00 – –
Laparoscopic 1.15 0.81–1.62 0.429
Year of RP 493 1.07 0.90–1.27 0.441
Prediagnostic PSA level (ng/ml) 489 1.03 1.01–1.05 0.002 1.00 0.98–1.02 0.866
Prediagnostic PSA level 489
<4 ng/ml 1.00 – –
4–10 ng/ml 3.02 0.95–9.58 0.061
¸10 ng/ml 4.99 1.57–15.89 0.006
Gleason score at RP 478
<7 1.00 – – 1.00 – –
7 2.55 1.77–3.68 <0.001 1.71 1.13–2.60 0.012
>7 4.39 2.64–7.31 <0.001 2.55 1.43–4.52 0.001
Pathological stage (pTNM) 483
pT2 1.00 – – 1.00 1.00 –
pT3 or pT4 2.50 1.79–3.50 <0.001 1.68 1.13–2.49 0.010
Extracapsular extension 386 2.41 1.62–3.58 <0.001
Positive surgical margins 470 4.33 2.94–6.38 <0.001 2.85 1.87–4.35 <0.001
Invasion seminal vesicles 480 2.58 1.64–4.04 <0.001
Positive lymph nodesc 489 2.93 1.54–5.58 0.001 1.57 0.80–3.07 0.186123
World J Urolto be further elucidated, since BMI itself was not an inde-
pendent predictor of BCR after RP.
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